Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
The Daily Current Affairs Quiz which keeps you updated with the current events happening all…
Traffic congestion is a serious problem in many Asian cities, affecting millions of people every…
Uttar Pradesh is a state rich in culture, history, and religious significance. Among its many…
Many countries around the world have unique nicknames that reflect their culture, history, or geography.…
The World Day of Remembrance for Road Traffic Victims (WDR) is observed on the third…
On the occasion of the inauguration of Symbiosis International University’s first international campus at Dubai…